Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
Karine Briot, Anthony A. Portale, Maria Luisa Brandi, et al.
RMD Open (2021) Vol. 7, Iss. 3, pp. e001714-e001714
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients with X-Linked Hypophosphatemia
Dalal S. Ali, Reza Mirza, Salma Hussein, et al.
The Journal of Clinical Endocrinology & Metabolism (2025)
Open Access | Times Cited: 1
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
Dieter Haffner, Francesco Emma, Lothar Seefried, et al.
Nature Reviews Nephrology (2025)
Open Access | Times Cited: 1
X‐Linked Hypophosphataemia and Burosumab: A Systemic Disease With a New Treatment
Jessica Sandy, Andrew Biggin, Aris Siafarikas, et al.
Journal of Paediatrics and Child Health (2025)
Open Access | Times Cited: 1
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
Peter Kamenický, Karine Briot, Maria Luisa Brandi, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e002676-e002676
Open Access | Times Cited: 19
Health-related quality of life of X-linked hypophosphatemia in Spain
María I. Luis Yanes, Díaz Curiel M, Pilar Peris, et al.
Orphanet Journal of Rare Diseases (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 26
Asia‐Pacific Consensus Recommendations on X‐Linked Hypophosphatemia: Diagnosis, Multidisciplinary Management, and Transition from Pediatric to Adult Care
Craig Munns, Han‐Wook Yoo, Muhammad Yazid Jalaludin, et al.
JBMR Plus (2023) Vol. 7, Iss. 6
Open Access | Times Cited: 13
Phosphatonins: From Discovery to Therapeutics
Kittrawee Kritmetapak, Rajiv Kumar
Endocrine Practice (2022) Vol. 29, Iss. 1, pp. 69-79
Open Access | Times Cited: 20
Improved Oral Health in Adults with X-Linked Hypophosphatemia Treated with Burosumab
Agathe Hervé, Margaux Gadion, Julia Herrou, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 4
Qualitative analysis of pain impact in adult patients with X-linked hypophosphatemia
Nicole Nishime, Christopher B. Theriault, Richard Feinn, et al.
JBMR Plus (2025)
Open Access
Factors associated with impaired physical functionality in x-linked hypophosphatemia
Danisa Ivanovic‐Zuvic, Annette Madison, Macarena Jiménez, et al.
JBMR Plus (2025) Vol. 9, Iss. 4
Open Access
XLH Matters: an evolving programme to discuss new advances and share clinical experiences to improve patient outcomes
Lothar Seefried, Ferdinando Aliberti, Cathrine Alsaker Heier, et al.
Orphanet Journal of Rare Diseases (2025) Vol. 19, Iss. S2
Open Access
X-bundet hypofosfatemi
Qi Wang, Cennet Akdeniz, Ansgar Heck, et al.
Tidsskrift for Den norske legeforening (2025)
Open Access
Quality of life of 26 family members from four generations with X-linked hypophosphatemia: a cross-sectional study
Afaf Alsagheir, Bassam Bin‐Abbas, Nujud M. Alghamdi, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline
Aliya Khan, Dalal S. Ali, Natasha M. Appelman‐Dijkstra, et al.
The Journal of Clinical Endocrinology & Metabolism (2025)
Open Access
Metabolically healthy obesity in adults with X-linked hypophosphatemia
Anne-Lise Lecoq, Katharina Schilbach, L. Rocher, et al.
European Journal of Endocrinology (2024) Vol. 191, Iss. 2, pp. 156-165
Closed Access | Times Cited: 3
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study
Maria Luisa Brandi, Suzanne M. Jan de Beur, Karine Briot, et al.
Calcified Tissue International (2022) Vol. 111, Iss. 4, pp. 409-418
Closed Access | Times Cited: 13
Burosumab: Current status and future prospects
Alpesh Goyal, Nikhil Tandon
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 38, Iss. 2, pp. 101826-101826
Closed Access | Times Cited: 7
Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts
María Helena Vaisbich, Antônio César Paulillo de Cillo, Barbara C. Silva, et al.
Molecular Genetics & Genomic Medicine (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 2
Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients with X-Linked Hypophosphatemia
Dalal S. Ali, Reza Mirza, Farah Alsarraf, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 2
Impact of X-Linked Hypophosphatemia on Muscle Symptoms
Cecilia Romagnoli, Teresa Iantomasi, Maria Luisa Brandi
Genes (2022) Vol. 13, Iss. 12, pp. 2415-2415
Open Access | Times Cited: 9
Clinical performance of a new intact FGF23 immunoassay in healthy individuals and patients with chronic hypophosphatemia
Hajime Katô, Hiromi Miyazaki, Takehide Kimura, et al.
Bone Reports (2023) Vol. 18, pp. 101659-101659
Open Access | Times Cited: 5
Efficacy and Safety of Burosumab in X-linked Hypophosphatemia
S S Wang, Xiaoqin Wang, Miao He, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 109, Iss. 1, pp. 293-302
Closed Access | Times Cited: 5
X-Linked Hypophosphatemia, Not Only a Skeletal Disease But Also a Chronic Inflammatory State
Marie-Noëlle Méaux, Candide Alioli, Agnès Linglart, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 12, pp. 3275-3286
Open Access | Times Cited: 8
New treatments for rare bone diseases: hypophosphatemic rickets/osteomalacia
Júlia Vieira Oberger Marques, Carolina Aguiar Moreira, Victória Zeghbi Cochenski Borba
Archives of Endocrinology and Metabolism (2022) Vol. 66, Iss. 5, pp. 658-665
Open Access | Times Cited: 8
A patient-centred and multi-stakeholder co-designed observational prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphataemia (XLH)
Vrinda Saraff, Annemieke M. Boot, Agnès Linglart, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0295080-e0295080
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top